Novartis has added another component to its "Clinical Trials of the Future" program. The latest element of the trial efficiency initiative sees the Swiss Big Pharma team up with computer chip maker Qualcomm to gather data on clinical trial participants between visits to the investigator site.
The FDA has released a list of almost 100 draft drug guidance documents it plans to introduce or update in 2015. The documents cover a range of biotech IT-related topics, including electronic informed consent in clinical trials, links to third-party sites in social media adverts and statistical approaches to showing biosimilarity.
GlaxoSmithKline and Medidata have moved mHealth tools one step closer to the clinical trial mainstream. Having run a pilot project, the partners have concluded that mHealth technologies can deliver reliable, FDA-compliant data and improve the clinical trial experience for patients.
Thermo Fisher Scientific has confirmed its Kinetica software will generate inaccurate results when analyzing unbalanced clinical trials, Reuters reports.
In the years since the Affordable Care Act birthed the Patient-Centered Outcomes Research Institute, the group has committed resources to lowering barriers between those who participate in and run clinical trials. The latest element of this initiative has now come to fruition, with PCORI naming PatientPowered.us as the winner of its Matchmaking App Challenge.
The U.S. National Cancer Institute is working with Dell, Terascala and the Translational Genomics Research Institute to bolster its pediatric oncology research capabilities. The NCI ultimately hopes to use the new computing capabilities to discover new biomarkers and therapeutic targets for childhood cancers.
The study aims to recruit 40 people in the United Kingdom to wear watch-sized sensors on their belts. By placing the sensors around the body's center of mass the team from Imperial College London hope to gather data on each individual's position and walking speed.
Mayo Clinic and IBM have teamed up to apply cutting-edge technology to the age-old problem of enrolling patients into clinical trials. Starting next year Mayo Clinic will use IBM's supercomputer Watson to automatically match patients to clinical trials.
Illumina has laid the groundwork for increased use of next-generation sequencing in clinical research by striking a deal with Big Pharma, which could result in the company disrupting diagnostics using its dominance in NGS.
Intel has spent the past year adding tools for gathering and analyzing data, notably by taking a stake in Cloudera and buying Basis. And the strategy now has a major test case, with the Michael J. Fox Foundation teaming up with Intel to remotely monitor people with Parkinson's disease.